1-9 of 9
Jason Shafrin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia

Free
Jennifer Vaughn, Nadine Zawadzki, Caroline Hardy, Gabriel Marquez, Gopi Madhav Bommidi, Poornima Sachin Dhobe, Sai Vasmi Gedala, Islam Mohamad Sadek, Jason Shafrin, David Wei
Journal: Blood
Blood (2025) 146 (Supplement 1): 2835.
https://doi.org/10.1182/blood-2025-2835
Published: 2025
Journal Articles

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Free
Farrukh Awan, Nadine Zawadzki, Anna Teschemaker, Kathy Wojtas, David Satre, Vikram Shetty, Dipen Patel, Fady Fam, Ryan Crowley, Jason Shafrin
Journal: Blood
Blood (2025) 146 (Supplement 1): 2627.
https://doi.org/10.1182/blood-2025-2627
Published: 2025
Journal Articles

Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL

Free
Tara Graff, Savreet Bains Chawla, Monika Jun, Nicole Heaps, Abualbishr Alshreef, David Tybor, Nadine Zawadzki, Kathryn Spurrier, Jason Shafrin
Journal: Blood
Blood (2025) 146 (Supplement 1): 7942.
https://doi.org/10.1182/blood-2025-7942
Published: 2025
Journal Articles

Cost-Offset Analysis Performed Utilizing Covalent Bruton's Tyrosine Kinase Inhibitors Safety Profiles Among Medicare Patients with Chronic Lymphocytic Leukemia

Free
Adam S Kittai, Dipen A. Patel, Jason Shafrin, Nadine Zawadzki, Vikram Shetty, Khounish Sharma, Yazan K. Barqawi, Joanna M. Rhodes
Journal: Blood
Blood (2024) 144 (Supplement 1): 5031.
https://doi.org/10.1182/blood-2024-201039
Published: 2024
Journal Articles

Financial Impact of Treatment Choice in CML: A Comparison of Later Generation TKIs Versus Imatinib for US Patients and Payers

Free
Jason Shafrin, Nadine Zawadzki, Shurui Zhang, Paul Pinkston, David Wei, Jennifer E Vaughn
Journal: Blood
Blood (2024) 144 (Supplement 1): 3677.
https://doi.org/10.1182/blood-2024-201000
Published: 2024
Journal Articles

Cost to Treat Newly Diagnosed Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis

Free
Anem Waheed, Denise Clayton, Jason Shafrin, Frank Li, Yulin Shi, Lincy Geevarghese, Glorian P. Yen
Journal: Blood
Blood (2022) 140 (Supplement 1): 5033–5034.
https://doi.org/10.1182/blood-2022-158358
Published: 2022
Journal Articles

How Does Sickle Cell Disease Severity Affect Patient Collection of Disability Insurance and Income: An Analysis of US Survey Data

Free
Jason Shafrin, Howard Z. Thom, Daisy Gaunt, Lauren M. Zhao, George J Joseph, Menaka Bhor, PhD, Avery A. Rizio, Lanetta Bronté-Hall, MPH, MSPH, MD, Nirmish Shah
Journal: Blood
Blood (2019) 134 (Supplement_1): 5781.
https://doi.org/10.1182/blood-2019-122774
Published: 2019
Journal Articles

Quantifying the Economic Burden of Myelodysplastic Syndromes Among Elderly US Patients

Free
Jason Shafrin, PhD, Sarah Green, BA, Richard Murphy, BA, Katie Everson, MS, Syvart Dennen, M.Phil, Kwanza Price, MPH, Katharine Batt, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2151.
https://doi.org/10.1182/blood-2019-124216
Published: 2019
Journal Articles

Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States

Free
Howard Z. Thom, Jason Shafrin, Edna Keeney, Lauren M. Zhao, George J Joseph, Menaka Bhor, PhD, Avery A. Rizio, Lanetta Bronté-Hall, MPH, MSPH, MD, Nirmish Shah
Journal: Blood
Blood (2019) 134 (Supplement_1): 4700.
https://doi.org/10.1182/blood-2019-124132
Published: 2019